HUMA Humacyte, Inc. stock chart & analysis
Conviction 36HealthcareScan · Fri, Nov 6, 2026Humacyte, Inc. (HUMA) closed at $0.4482 (+13.32%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 49, RS Rating 7, -70.7% from its 52-week high, -53.5% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).
Why HUMA moved
From the StockSetups movers recaps that covered HUMA, newest first. A recap states what was known that day.
- Close+27.3%
The primary filing on file is a Schedule 13D/A (an amended ownership stake disclosure) filed August 18, signaling that a significant shareholder changed their position. No specific press release or earnings catalyst is available in the data.
Top Stock Movers Today — August 19, 2026: Why MRNA, CYPH, PURR, HUMA & MRVI Surged →
Financials as of Tue, Jun 30, 2026 · quarterly.
HUMA technical analysis
Trend
HUMA is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 10.4% below the 50-day ($0.4985) and 43.5% below the 200-day ($0.7907). ADX(14) at 21 points to a moderate trend. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 49, in the bearish half of its range. The MACD histogram is positive. Its RS Rating of 7 puts its weighted 12-month performance ahead of about 7% of the US market.
Volume and volatility
Volume on the latest session ran 0.7× its 20-day average. It trades about $2.5M a day on average. ATR(14) is $0.0480, 10.7% of price — its typical daily range. Chaikin Money Flow (-0.09) shows distribution.
Key levels
The chart pattern's support is $0.3610 and its resistance $0.5599. The 52-week range is $0.3370 to $1.53; price is 70.7% below the high and 32.6% above the low. The VWAP anchored at the 52-week high is $0.6864, above price.
Performance
HUMA returned +8.6% (1 week), -0.1% (1 month), -40.0% (3 months), -57.9% (6 months), -69.2% (1 year), -53.5% (year to date).
About Humacyte, Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Biological Products, (No Diagnostic Substances) · Listed 2021 · 184 employees
Congress activity
Disclosed STOCK Act trades in HUMA · 10 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Thomas H Tuberville senate · traded 2024-05-03 | Sell | $1K–$15K | 2024-05-03 | 2026-08-05 | |
Thomas H Tuberville senate · traded 2024-05-03 | Sell | $15K–$50K | 2024-05-03 | 2026-08-05 | |
Thomas H Tuberville senate · traded 2024-03-21 | Buy | $1K–$15K | 2024-03-21 | 2026-08-05 | |
Thomas H Tuberville senate · traded 2024-03-21 | Buy | $15K–$50K | 2024-03-21 | 2026-08-05 | |
Thomas H Tuberville senate · traded 2024-05-03 | Sell | $1K–$15K | 2024-05-03 | 2024-06-14 | |
Thomas H Tuberville senate · traded 2024-05-03 | Sell | $15K–$50K | 2024-05-03 | 2024-06-14 | |
Thomas H Tuberville senate · traded 2024-04-30 | Sell | $50K–$100K | 2024-04-30 | 2024-05-15 | |
Thomas H Tuberville senate · traded 2024-03-21 | Buy | $1K–$15K | 2024-03-21 | 2024-04-15 | |
Thomas H Tuberville senate · traded 2024-03-21 | Buy | $15K–$50K | 2024-03-21 | 2024-04-15 | |
Thomas H Tuberville senate · traded 2024-02-12 | Buy | $15K–$50K | 2024-02-12 | 2024-03-15 |
Insider activity
SEC Form 4 transactions in HUMA · open-market 4 buys · 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Kuznik Paul Brian Director · Stock Options (right to buy) · 2026-10-06 | Grant | 125K | — | 2026-10-06 | 2026-10-07 |
COWARD D SCOTT Director · Stock Options (right to buy) · 2026-10-06 | Grant | 125K | — | 2026-10-06 | 2026-10-07 |
Jones Keith Anthony Director · Common Stock · 2026-09-14 | Buy | 10K | $6K | 2026-09-14 | 2026-09-15 |
Jones Keith Anthony Director · Common Stock · 2026-08-20 | Buy | 10K | $7K | 2026-08-20 | 2026-08-21 |
Jones Keith Anthony Director · Common Stock · 2026-08-17 | Buy | 30K | $18K | 2026-08-17 | 2026-08-19 |
Bamforth John Philip Director · Stock Options (right to buy) · 2026-06-11 | Grant | 80K | — | 2026-06-11 | 2026-06-12 |
Sebelius Kathleen Director · Common Stock · 2026-05-19 | Buy | 56.82K | $50K | 2026-05-19 | 2026-05-20 |
Parikh Shamik J Chief Medical Officer · Common Stock · 2026-05-18 | Sell | 45.89K | $41K | 2026-05-18 | 2026-05-20 |
Sander Dale A. CFO and Chief Corp. Dev. Off · Common Stock · 2026-05-18 | Sell | 45.89K | $41K | 2026-05-18 | 2026-05-20 |
Sander Dale A. CFO and Chief Corp. Dev. Off · Common Stock · 2026-05-18 | Other | — | — | 2026-05-18 | 2026-05-20 |
SEC filings
EDGAR filings in HUMA · 10 recent
- 8-K8-KMon, Sep 28, 2026
- 13D/GSCHEDULE 13D/ATue, Aug 18, 2026
- 10-K/Q10-QWed, Aug 12, 2026
- 8-K8-KWed, Aug 12, 2026
- 8-K8-KFri, Jul 31, 2026
- 13D/GSCHEDULE 13G/ATue, Jul 28, 2026
- 13D/GSCHEDULE 13D/AMon, Jul 13, 2026
- 13D/GSCHEDULE 13GMon, Jun 22, 2026
- 13D/GSCHEDULE 13D/AMon, Jun 15, 2026
- OFFER424B5Thu, Jun 11, 2026
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.